(NYSE: ZTS) Zoetis's forecast annual revenue growth rate of 5.72% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 37.1%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.74%.
Zoetis's revenue in 2025 is $9,397,000,000.On average, 21 Wall Street analysts forecast ZTS's revenue for 2026 to be $4,412,220,458,568, with the lowest ZTS revenue forecast at $4,208,620,193,700, and the highest ZTS revenue forecast at $4,656,805,192,338. On average, 19 Wall Street analysts forecast ZTS's revenue for 2027 to be $4,662,534,204,120, with the lowest ZTS revenue forecast at $4,408,254,219,642, and the highest ZTS revenue forecast at $4,932,238,451,088.
In 2028, ZTS is forecast to generate $4,883,762,197,548 in revenue, with the lowest revenue forecast at $4,576,158,334,176 and the highest revenue forecast at $5,286,555,795,144.